CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 706 enrolled
Drug / intervention
Telmisartan 80 +2 moredrug
Likely dose
Telmisartan 80 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00877929
NCT00877929Phase 3Completed

An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.

Boehringer Ingelheim·interventional·Posted Apr 8, 2009·Updated Mar 12, 2014

In Brief

A Phase 3 clinical trial evaluating Telmisartan 80 and Amlodipine 10 for Hypertension. Completed, enrolled 706 participants across 65 sites in 9 countries.

Detailed Summary

To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesArgentina, Mexico, Netherlands, Slovakia, South Africa, South Korea, Spain, Sweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 8, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.2 years ago

Interventions

Telmisartan 80drug

Telmisartan 80 mg

Amlodipine 10drug

Amlodipine 5 for two weeks, then forced titration to Amlodipine 10

Amlodipine 10drug

Amlodipine 5 for two weeks, then forced titration to Amlodipine 10